These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23067221)

  • 1. Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma.
    Usakova V; Sevcikova K; Usak J; Bartosova Z; Mikulova M; Spanik S
    Neoplasma; 2013; 60(1):83-91. PubMed ID: 23067221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical use of capecitabine plus oxaliplatin (CAPEOX) with bevacizumab for patients with metastatic colorectal cancer that cannot expect conversion therapy.
    Yokomizo H; Yoshimatsu K; Otani T; Osawa G; Nakayama M; Matsumoto A; Yano Y; Okayama S; Naritaka Y
    Hepatogastroenterology; 2013; 60(128):1911-5. PubMed ID: 24719926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
    Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
    Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Specific treatment situations in metastatic colorectal cancer].
    Arnold D; Schmoll HJ; Lang H; Knoefel WT; Ridwelski K; Trarbach T; Staib L; Kirchner T; Geissler M; Seufferlein T; Amthauer H; Riess H; Schlitt HJ; Piso P
    Onkologie; 2010; 33 Suppl 4():8-18. PubMed ID: 20431307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
    Tsutsumi S; Fujii T; Yamaguchi S; Suto T; Yajima R; Morita H; Kato T; Asao T; Kuwano H
    Hepatogastroenterology; 2014 May; 61(131):633-7. PubMed ID: 26176048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
    Nitzkorski JR; Farma JM; Watson JC; Siripurapu V; Zhu F; Matteotti RS; Sigurdson ER
    Ann Surg Oncol; 2012 Feb; 19(2):379-83. PubMed ID: 21861213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
    Tomoda M; Kawahara H; Watanabe K; Enomoto H; Akiba T; Yanaga K
    Anticancer Res; 2014 Jan; 34(1):191-4. PubMed ID: 24403461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients.
    Ganapathi AM; Westmoreland T; Tyler D; Mantyh CR
    J Am Coll Surg; 2012 Apr; 214(4):582-8; discussion 588-90. PubMed ID: 22321523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
    Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
    J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma.
    Shah SA; Haddad R; Al-Sukhni W; Kim RD; Greig PD; Grant DR; Taylor BR; Langer B; Gallinger S; Wei AC
    J Am Coll Surg; 2006 Mar; 202(3):468-75. PubMed ID: 16500252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases.
    Yoshita H; Hosokawa A; Ueda A; Ando T; Kajiura S; Kato H; Kawabe H; Tomizawa G; Horikawa N; Yabuhita K; Note M; Sugiyama T
    Digestion; 2014; 89(1):43-8. PubMed ID: 24458112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for the requirement of surgical or endoscopic interventions during chemotherapy in patients with uncomplicated colorectal cancer and unresectable synchronous metastases.
    Yun JA; Park Y; Huh JW; Cho YB; Yun SH; Kim HC; Lee WY; Chun HK
    J Surg Oncol; 2014 Dec; 110(7):839-44. PubMed ID: 25043872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology.
    Cartwright TH; Yim YM; Yu E; Chung H; Halm M; Forsyth M
    Clin Colorectal Cancer; 2012 Dec; 11(4):238-46. PubMed ID: 22658457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents.
    Roddy JV; Partridge SM; Rockey ML; Pruemer JM; Guo JJ; Desai SJ; Safa MM
    Am J Clin Oncol; 2010 Feb; 33(1):36-42. PubMed ID: 19652579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival.
    Gruenberger T; Arnold D; Rubbia-Brandt L
    Surg Oncol; 2012 Dec; 21(4):309-15. PubMed ID: 22884035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
    Renouf DJ; Lim HJ; Speers C; Villa D; Gill S; Blanke CD; O'Reilly SE; Kennecke H
    Clin Colorectal Cancer; 2011 Jun; 10(2):97-101. PubMed ID: 21859560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.